



09/30/03

16248

CASE CT2614 NP

#7

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10EV984308331US
Express Mail Label NumberSeptember 29, 2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

OCT 06 2003

TECH CENTER 1600/2800

IN RE APPLICATION OF
DWORETZKY ET AL.

Art Unit: 1624

Examiner: Dr. Thomas C. McKenzie

APPLICATION NO: 10/075,703
FILED: FEBRUARY 14, 2002FOR: MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE
THEREOF IN TREATING MIGRAINE AND
MECHANISTICALLY RELATED DISEASECommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This paper is being filed in response to the Office Action mailed June 27, 2003 having a term that expired on July 27, 2003. A Petition for a two (2)-month Extension of Time to extend the time for response to the Official Action up to and including September 27, 2003, together with an authorization to charge the \$410.00 requisite extension fee to Deposit Account No. 19-3880, is enclosed herewith. Since September 27, 2003 was a Saturday, the present Response is being filed on the next business day.

Information Disclosure Statement

With respect to the Information Disclosure Statement filed June 11, 2002, the Patent Office states that "copies of the U.S. Patents are with the file but none of the other publications were attached."

EL984308331US

Although applicants believe that copies of these references were supplied with the Information Disclosure Statement filed June 11, 2002, applicants enclose herewith copies of the non-patent documents that appear on the Statement.

Elections/Restrictions

In reply to the Official Action mailed June 27, 2003, requesting an election of one invention to prosecute in the above-referenced patent application, applicants hereby provisionally elect the invention of Group I, encompassing claims 1-11 and drawn to oxindole compounds of formula I, page 13, for prosecution at this time. This election is made without prejudice to, or disclaimer of, the other claims or inventions disclosed; applicants reserve the right to file subsequent applications addressing non-elected subject matter.

Although it is believed no additional fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880. Furthermore, if any extension of time is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to Deposit Account Number 19-3880.

Respectfully submitted,



John A. Lamerdin, Ph.D.
Attorney for Applicants
Reg. No. 44,858

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3575

Date: September 29, 2003